维甲酸受体激动剂AM80抗阿尔治海默症最新研究进展

发布时间：2018-04-27 07:43

本文选题：他米巴罗汀 + 阿尔治海默症　；参考：《沈阳药科大学学报》2017年11期

【摘要】：目的综述AM80他米巴罗汀(tamibarotene,AM80)抗阿尔治海默症(Alzheimer's Disease,AD)药理作用及其作用机制、不良反应以及临床用药安全等最新研究进展。方法通过阅读近几年国内外的相关文献,对AM80抗阿尔治海默症最新研究报道进行详细的归纳总结。结果 AM80是一个合成的维甲酸受体激动剂,具有很好的抗阿尔治海默症作用。AM80作为一个多靶点药物,它通过转录调控多种与AD发病相关的基因;能够减少β淀粉样肽在脑部的沉积;还能够改善AD小鼠的学习记忆功能;有效弥补脑内乙酰胆碱的减少;并且能够增加小胶质细胞对Aβ(beta amyloid)的降解功能并伴随脑部炎症的减少。结论 AM80有望成为一个安全和有效的预防和治疗AD的药物,具有广泛的临床应用前景。
[Abstract]:Objective to review the recent progress in the pharmacological action, mechanism, adverse reactions and clinical safety of AM80 tambarote (AM80) against Alzheimer's disease (Alzheimer's disease / Alzheimer's disease). Methods the latest research reports on AM80 anti-Alzheimer's disease were summarized in detail by reading the relevant literature in recent years at home and abroad. Results AM80 is a synthetic retinoic acid receptor agonist, which has a good anti-Alzheimer 's effect. AM80 is a multi-target drug. It regulates many genes related to AD by transcriptional regulation. It can reduce the deposition of 尾 -amyloid peptide in the brain, improve the learning and memory function of AD mice, make up for the decrease of acetylcholine in the brain, and increase the degradation of A 尾 -beta amyloid by microglial cells and decrease the inflammation of brain. Conclusion AM80 is expected to be a safe and effective drug for the prevention and treatment of AD.
【作者单位】：广东药科大学生命科学与生物制药学院生物资源和创新药物研究中心;广东药科大学药学院广东省先导化合物与药物发现工程中心;
【基金】：广东省自然科学基金(No.2016A030313732) 广东省医学科学基金(No.A2015248)
【分类号】：R96

【相似文献】